Varivax

Varivax is a live, attenuated varicella virus vaccine (Oka/Merck strain) used to prevent chickenpox. It is produced in human diploid cells (MRC-5) and is administered via injection. This vaccine helps build immunity against the varicella-zoster virus. Store refrigerated to maintain potency.

Varivax is used to protect against chickenpox (varicella) by stimulating the immune system to produce antibodies. It is recommended for children and adults who have not had chickenpox or received the vaccine before. The vaccine is also used for post-exposure prophylaxis in certain cases. Varivax helps reduce the risk of infection and complications from varicella.

After vaccination, some people may experience mild effects such as redness, swelling, or pain at the injection site. A low-grade fever or mild rash may also occur. These effects are generally temporary and indicate the body’s immune response. Most individuals tolerate the vaccine well without significant discomfort.

Keep Varivax refrigerated at 2°C to 8°C (36°F to 46°F) and protect it from light. Do not freeze. Before use, inspect the vial for particles or discoloration. Discard if the solution appears cloudy or contains foreign particles. Ensure proper disposal of used syringes and needles.

Varivax may interact with immunosuppressive therapies, such as corticosteroids or chemotherapy, which can reduce vaccine effectiveness. Avoid vaccination during active febrile illnesses. Separate administration from other live vaccines by at least 4 weeks unless medically advised. Consult a healthcare provider if receiving blood products or immune globulins.